RxDoctor Payments Data

Brianna Barry, PA

Physician Assistant · Enterprise, ALNPI 1366062176

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (54.9%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. AbbVie accounts for 88.2% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $16,422, more than ten times the $750 reported in 2022. Among physician assistant clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$28,864in general payments, 2019–2025

Across 215 payments — averaging $134.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$25K
  • Sanofi$585
  • Johnson & Johnson$476
  • UCB, Inc.$438
  • Organogenesis Inc.$431
  • Regeneron Healthcare Solutions, Inc.$360
  • plus $1K from 11 others

What the payments were for

  • Speaking & faculty fees$15,83655%
  • Travel & lodging$7,24925%
  • Food & beverage$5,40219%
  • Education$3771%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,864 in reported general payments places this provider in the 95th percentile of 846 physician assistant providers in Alabama.

See all physician assistant providers in Alabama

Medicare billing

Part B allowed, 2024
$156,082
Medicare patients
767
Services billed
3,154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa12$252,758
Dupixent PenDupilumab42$158,206
Cosentyx (2 Syringes)Secukinumab17$150,040
Cosentyx Unoready PenSecukinumab13$93,819
Clobetasol Propionate123$7,633
Fluorouracil28$3,752
Ketoconazole119$2,415
Doxycycline Hyclate96$2,402
Tacrolimus15$1,603
Tretinoin17$1,491
Triamcinolone Acetonide106$1,477
Betamethasone Dipropionate20$1,068
Clindamycin Phosphate27$916
Desonide11$915
Mupirocin90$780

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisCosentyx (2 Syringes)$200$150,04017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 846 physician assistant providers in Alabama.

Other physician assistant in Enterprise

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →